Advanced Cell Technology Announces Collaboration with Xgene Corporation to Assess Its Dermal Cell Technologies in Human Skin Models.ALAMEDA, Calif. -- Advanced Cell Technology, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :ACTC ACTC Apple Certified Technical Coordinator ACTC Almaden Cycle Touring Club ACTC Associated Colleges of the Twin Cities ACTC All Ceylon Tamil Congress (Sri Lanka) ACTC Association Canadienne de Télévision par Câble ) has entered into a collaboration agreement with Xgene Corporation of Sausalito, CA, to assess the performance of Advanced Cell Technology's dermatology technologies. In the collaboration, Advanced Cell Technology will provide the human embryonic stem cell-derived skin cells, and Xgene will provide its technology for reconstituting skin from cultured cells, to achieve the mutually beneficial Adj. 1. mutually beneficial - mutually dependent interdependent, mutualist dependent - relying on or requiring a person or thing for support, supply, or what is needed; "dependent children"; "dependent on moisture" development of advanced in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. human skin models. The goal of the collaboration is to test the functionality of embryonic skin cells in regenerating skin for numerous applications in medicine. "Our expertise in assembling complex multi-tissue constructs from cultured cells offers a solid platform for realizing the therapeutic potential of early progenitor cells, beginning with dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. progenitors
The Progenitors were a race of fictional beings in the Star Trek Universe created by Gene Roddenberry. ," said Warren Hoeffler, Ph.D., Xgene's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "The potential of progenitor cells for healing wounds, and restoring lost functionality to patient skin, while minimizing scarring, could be important for the future practice of dermatology." "We anticipate that our collaboration with Xgene and the use of their proprietary human skin equivalent technology will accelerate the development of our dermatology products," said Michael West, Ph.D., President and Chief Scientific Officer of Advanced Cell Technology. William Caldwell, CEO of Advanced Cell Technology said, "We believe that Dr. Hoeffler's vast experience while at Stanford University School of Medicine Stanford University School of Medicine is affiliated with Stanford University and is located at Stanford University Medical Center in Stanford, California, adjacent to Palo Alto and Menlo Park. , Department of Dermatology, has allowed him to commercialize technology that is recognized by the biotech, big pharma and cosmetic industries as revolutionary in nature. We look forward to commercializing with Xgene a product derived from human ES cells." About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com. Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-KSB for the fiscal year ended December 31, 2005. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion